Psilocybin was tolerated in 14 people with bipolar II depression, with no mania reported.
The open-label, single-arm trial started at 10 mg and escalated to 25 mg if symptoms persisted, with therapy around each session. Cardiovascular changes were transient; the primary depression endpoint came 21 days after the final dose.